QDEL - Earnings announcements

SAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 RevenueThe Company currently expects preliminary unaudited revenue, as reported, o

― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagno

SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "

― Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations ― ― Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing ―  Third Quarter 2025 Results(all comparisons are to the prior year period)                                   Total revenue was $700 million, as reportedNon-respiratory revenue was $588 million, an increase of 5% as reported and 4% in constant currency; excluding Donor S

SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relat

― Labs revenue grew 4% as reported and 5% in constant currency ―― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results(all comparisons are to the prior year period) Total revenue was $614 million, as reportedNon-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currencyLabs revenue grew 4% as reported and 5% in constant currencyImmunohematology revenue grew 4% as reported and 3% in constant currencyRespiratory

SAN DIEGO, July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2025 ended June 29, 2025, after the market close on Tuesday, August 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested

―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company") or ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.c

Strong finish to 2024 with continued progress in cost-savings initiatives to drive adjusted EBITDA margin expansion in 2025 and beyond Company issues full-year 2025 financial guidance Fourth Quarter and Full-Year 2024 Results (all comparisons are to the prior year period) Fourth quarter 2024 revenue was $708 million, as reported Non-respiratory revenue was $565 million, which was flat compared to the prior year period due to a decline in U.S. Donor Screening revenue, a business the Company is exiting; Labs revenue grew 4%, as reported and in constant currency, excluding COVID-19 and non-core revenues1 Respiratory revenue was $143 million, a decrease of 18%, as reported and in co

Top-line Results In Line with Expectations; Company Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. Fourth Quarter 2024 Preliminary Unaudited Revenues The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately $702 million to $707 million, which would be in line with its previously announc

― Company reinstates 2024 financial guidance ― ― Drives cost-savings and growth initiatives ― ― Strengthens leadership team and aligns organization for improved effectiveness ― Third Quarter 2024 Results and Recent Developments (all comparisons are to the prior year period) Reported revenue was $727 million Recurring revenue1 was $598 million as reported with no significant change in constant currency, excluding COVID-19 and U.S. Donor Screening revenue Labs revenue grew 4% as reported and 5% in constant currency GAAP operating expenses2 of $242 million decreased by $13 million; non-GAAP operating expenses of $232 million decreased by $17 million, reflecting ongoing implementa

QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its third quarter 2024 ended September 29, 2024, after the market close on Thursday, November 7, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelort

— $100 million in annualized cost-savings initiatives will benefit second half 2024 and first half 2025 — — Strong progress on business review and refocusing R&D investments on core growth areas —  Second quarter 2024 revenue was $637 million, as reported: Total recurring revenue1 grew 3% as reported and 5% in constant currency compared to the prior year period, excluding COVID-19 revenue and U.S. Donor Screening revenue YTD 2024 revenue was $1.35 billion, as reported: Total recurring revenue1 grew 6% as reported and 7% in constant currency compared to the prior year period, excluding COVID-19 revenue, a one-time third-party collaboration settlement and U.S. Donor Screening rev

QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2024 ended June 30, 2024, after the market close on Wednesday, July 31, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.co

- Global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue - - Cost reduction initiatives well underway, headcount reductions expected to deliver approximately $100 million in annualized savings - - Company suspends 2024 financial guidance while it assesses business under new President and Chief Executive Officer - First Quarter 2024 Results and Recent Highlights Revenue was $711 million, as reported: Non-respiratory revenue was flat at $574 million compared to the prior year period, as reported and in constant currency Excluding the one-time third-party settlement of $21 million in the prior year period, non-respiratory revenue

QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.com/. Presenta

Strong momentum in Labs business, with solid non-respiratory business growth and market share gains in industry-leading respiratory point-of-care portfolio Fourth Quarter 2023 Results and Highlights Revenue was $743 million, as reported: Non-respiratory revenue increased by 9% as reported and in constant currency Respiratory revenue decreased by 49% as reported and in constant currency GAAP net cash provided by operating activities was $80 million; adjusted free cash flow was $89 million Received 510(k) clearance for Savanna multiplex molecular platform and HSV/VZV PCR assay Received CLIA waiver for Sofia® 2 SARS Antigen+ FIA Full-Year 2023 Results and Highlights

QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Tuesday, February 13, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir

Broad strength in respiratory and core businesses across all geographies, driven by execution, customer excellence and improved operational efficiencies Highlights Third quarter revenue was $744 million, as reported, driven by strong respiratory demand and continued strength in non-respiratory businesses Non-respiratory revenue increased by 2% as reported and in constant currency, compared to the prior year period, driven by growth in the Labs business, which continues to perform to expectations Respiratory revenue decreased by 21% as reported and in constant currency, primarily due to the anticipated decline in COVID-19 revenue compared to the prior year period Growth across a

Earlier-than-expected demand for respiratory products in core markets drives strong preliminary performance Company to report third quarter 2023 financial results on November 1, 2023 QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced strong preliminary unaudited revenue results for the fiscal third quarter ended October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu. Third Quarter 2023 Preliminary Unaudited Revenue Results Total revenues of $738 million to $744 mi

QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2023 ended July 2, 2023, after the market close on Tuesday, August 8, 2023. Following the release of the financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho

Highlights First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in constant currency) and respiratory revenue down 72% on a supplemental combined basis Growth in non-respiratory revenue for the first quarter was driven by the Labs business unit, primarily due to heightened instrument delivery and testing demand First quarter GAAP EPS of $0.73; adjusted EPS of $1.80, a 78% decrease from prior year on a supplemental combined basis, largely reflecting the strength of respiratory revenue in the first quarter of 2022 QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a glob

QuidelOrtho to report first quarter 2023 financial results on May 3, 2023 QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the first quarter ended April 2, 2023. The Company expects total revenues in the first quarter of 2023 to be in the range of $840 million to $850 million. Respiratory product revenue is expected to be in the range of $262 million to $267 million, including COVID-19 product revenue of $212 million to $217 million. Non-respiratory product revenue is expected

Highlights Fourth quarter revenue of $866.5 million increased by 36% as reported and 19% on a supplemental combined basis, excluding COVID-19 revenue Full year revenue of $3.27 billion increased by 92% as reported; Supplemental combined revenue of $4.05 billion increased by 11%, excluding COVID-19 revenue Growth in revenue, excluding COVID-19 revenue, for both the fourth quarter and full year, was driven by Point of Care and Molecular Diagnostics, partially offset by weakness in Labs due to China lockdowns and global supply chain challenges Fourth quarter GAAP EPS of $0.45; Supplemental combined adjusted EPS of $1.76, a 66% decrease from prior year, largely reflecting the strength o

QuidelOrtho to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue results for the fourth quarter and full year ended January 1, 2023. The Company expects total revenues in the fourth quarter of 2022 to be in the range of $853 million to $868 million. COVID-19 product revenue is expected to be in the range of $124 million to $134 million and non-COVID-19 product revenue is expected to be in the range of $

Highlights Revenue of $783.8 million increased by 54% as reported Supplemental combined revenue of $783.8 million decreased by 21.8% in constant currency and increased 3.0%, excluding COVID-19 revenue; the transition of Beckman BNP assay sales to Beckman was a 3 percentage point headwind to revenue so the underlying base business increased 6.0% Growth in revenue, excluding COVID-19 revenue, was driven by Point-of-Care and Donor Screening product lines Strength in North America, LATAM, and ASPAC was partially offset by weakness in China and EMEA GAAP EPS of $0.28; Supplemental combined adjusted EPS of $1.85, a (54)% decrease from prior year, largely reflecting the strength of high

QuidelOrtho to Report Third Quarter 2022 Financial Results on November 2, 2022 QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the third quarter ended October 2, 2022. The Company expects total revenues in the third quarter of 2022 to be in the range of $782 million to $785 million. COVID-19 product revenue is expected to be approximately $171 million and non-COVID-19 product revenue is expected to be in the range of $611 million to $614 million. COVID-19 product revenue includ

Highlights Revenue of $613.4 million increased by 247% as reported; Supplemental combined revenue of $898.5 million increased by 37.5% in constant currency and 9.0%, excluding COVID-19 revenue Strong growth in all business units, excluding COVID-19 revenue, including double-digit growth in Point-of-Care and Molecular Diagnostics, and high-single-digit combined growth in Labs and Transfusion Medicine Strength across all major regions, including China, EMEA, and North America GAAP EPS of $0.36; Supplemental combined adjusted EPS of $2.12, a 123% increase from prior year, largely reflecting the strength of high margin COVID-19 revenue QuidelOrtho Corporation (NASDAQ:QDEL) (the "Co

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a leading in vitro diagnostics company, today announced it will report financial results for its second quarter 2022 ended July 3, 2022, after the market close on Thursday, August 4, 2022. Following the release of the financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss the financial results. Interested parties can access the conference call on the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/. Those unable to access the webcast may join the call via phone

Quidel Corporation (NASDAQ:QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights Total revenues increased 167% to $1,002.3 million, from $375.3 million in the first quarter of 2021. Total sales of COVID-19 products increased 211% to $836.1 million, from $269.1 million in the first quarter of 2021. Total sales of Influenza products were $89.1 million, as compared to $16.4 million in the first quarter of 2021. Reported GAAP EPS of $11.31 per diluted share in the first quarter of 2022, as compared to $4.09 per d

Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022 financial results after market close on Wednesday, May 4, 2022. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During the conference call, the company will also discuss business and financial developments and trends. The company's statements may contain or cons

Quidel Corporation (NASDAQ:QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Highlights Signed definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc ("Ortho"), funded through a combination of cash and newly issued shares in the combined company. Total revenue was $636.9 million, from $809.2 million in the fourth quarter of 2020. Revenue for COVID-19 products was $511.8 million, versus $405.3 million in the fourth quarter of 2020. Total Influenza revenue was $40.5 million (inclusive of

Quidel Corporation (NASDAQ:QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year 2021 financial results after market close on Thursday, February 17, 2022. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During the conference call, the company will also discuss business and financial developments and trends. The company's statements may con

Strategic, transformational acquisition advances Quidel's global leadership in diagnostics Transaction Highlights Brings together highly complementary diagnostic portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing. Provides Quidel's expansive point-of-care diagnostics portfolio with access to Ortho's broad global reach across 130-plus countries, accelerating growth for Quidel's existing product portfolio and providing exposure to new, emerging markets. Deepens innovation pipeline, diversifies product portfolio, and accelerates product growth, driving sustainable revenue in a combined total addressable market of $

Quidel Corporation (NASDAQ:QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highlights Total revenues increased 7% to $509.7 million, from $476.1 million in the third quarter of 2020. Total sales of COVID-19 products increased 7% to $402.6 million, from $375.7 million in the third quarter of 2020. Total sales of Influenza products were $13.8 million, compared to $9.0 million in the third quarter of 2020. Reported GAAP EPS of $5.08 per diluted share in the third quarter of 2021, as compared to $5.33 per diluted

Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal third quarter 2021 financial results after market close on Thursday, November 4, 2021. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During the conference call, the company will also discuss business and financial developments and trends. The company's statements may contain or

Quidel Corporation (NASDAQ:QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Highlights Total revenue decreased 12% to $176.6 million, from $201.8 million in the second quarter of 2020. Total sales of COVID-19 products were $83.4 million, as compared to $109.0 million in the second quarter of 2020. Total sales of Influenza products were $1.6 million, as compared to $18.7 million in the second quarter of 2020. Reported GAAP EPS of $0.45 per diluted share in the second quarter of 2021, as compared to $1.55 per dilute